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Abstract. The aim of the study is to evaluate the differences
of protein binding of NAMI-A, a new ruthenium drug
endowed with selective antimetastatic properties, and of
cisplatin and to ascertain the possibility to use two drugs
based on heavy metals in combination to treat solid tumour
metastases. For this purpose, we have developed a technique
that allows the proteins, to which metal drugs bind, to be
identified from real protein mixtures. Following incubation
with the drugs, the bands containing platinum and/or ruthenium
are separated by native PAGE, SDS-PAGE and 2D gel electro-
phoresis, and identified using laser ablation inductively coupled
plasma mass spectrometry. Both drugs interact with essentially
the same proteins which, characterised by proteomics, are
human serum albumin precursor, macroglobulin ·2 and human
serotransferrin precursor. The interactions of NAMI-A are
largely reversible whereas cisplatin forms stronger interactions
that are less reversible. These data correlate well with the MCa
mammary carcinoma model on which full doses of NAMI-A
combined with cisplatin show additive effects as compared to
each treatment taken alone, independently of whether NAMI-A
precedes or follows cisplatin. Furthermore, the implication from
this study is that the significantly lower toxicity of NAMI-A,
compared to cisplatin, could be a consequence of differences
in the mode of binding to plasma proteins, involving weaker
interactions compared to cisplatin.
Introduction
Cisplatin and the second-generation platinum drug, carboplatin,
are among the most successfully used anticancer drugs
available today, being used for treating a number of different
cancers, including testicular, ovarian, oropharyngeal and
bronchogenic cancers, cervical and bladder carcinomas,
lymphoma, osteosarcoma, melanoma and neuroblastoma (1).
However, platinum drugs have a high general toxicity which
leads to a number of side effects, among which nephrotoxicity
is particularly severe (2,3). Numerous complexes based on
metals other than platinum have been synthesised in order to
ameliorate the therapeutic properties of cisplatin and to reduce
its adverse effects, and some of them reached early clinical
evaluation (4), but failed to reach the clinic because almost
all showed relevant toxicity, even more severe than that of
cisplatin (5). Ruthenium-based anticancer drugs are proving to
be the exception (6) and one of them, ImH[Ru(Im)(Me2SO)Cl4]
(NAMI-A), shows a strong efficacy against solid tumour
metastases (7,8) with a general toxicity lower than that of
cisplatin, particularly on the kidney, which completely recovers
from mild epithelial damage after drug withdrawal (2).
NAMI-A has recently concluded a phase I clinical evaluation,
showing a relatively low toxicity and the absence of renal
toxicities at the maximum tolerated dose (9).
The most common method of cisplatin administration is
intravenous injection. However, other administration methods
have been evaluated in order to reinforce its effect, and also
to reduce the side effects. The interaction of cisplatin with
proteins has been investigated in some detail (10,11) and it
would appear that non-specific binding to thiol residues on
protein surfaces could take place. A large body of information
describing how platinum drugs induce cytotoxicity by cross-
linking DNA, causing structural changes that inhibit replication
and protein synthesis has also accumulated (12-14).
In general, data on the mechanism of action of NAMI-A
seem to exclude DNA as the primary target for its activity on
metastases (15-17), and binding to DNA is far weaker than
that of platinum complexes (18). Conversely, NAMI-A was
shown to bind tightly to serum albumin and serum transferrin,
two representative plasma proteins (19,20), suggesting that
binding to specific proteins may represent the molecular
basis for its peculiar biological activity. It was also suggested
that binding of ruthenium(III) complexes to serum transferrin
might help to target cancer cells taking advantage of the
specific receptor-binding mechanism of transferrin, but these
results remain controversial (21,22).
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Comparing the plasma proteins' interactions with the
platinum compound, cisplatin, and the newly developed
ruthenium compounds should contribute significantly to the
understanding of the delivery, mode of action, toxicity and
side effects of the investigated drugs. We therefore decided
to use a protocol developed in our laboratory (23) to study
these systems in vitro but under the complex environment of
the real system, and to discuss the results in the light of the
pharmacological effects of cisplatin and NAMI-A, used alone
or in combination, in a mouse model of solid metastasising
tumour.
Materials and methods
In vitro experiments. Human plasma, human serum albumin
(HSA) and transferrin were purchased from Sigma (St. Louis,
MO, USA), bovine serum albumin (BSA) was purchased from
Fluka (Buchs, Switzerland). A montage albumin deplete kit
was purchased from Millipore (Volketswil, Switzerland) and
trypsin was purchased from Promega (Wallisellen, Switzer-
land). Cis-diamineplatinum(II) (cisplatin) was purchased from
Lancaster (UK) and NAMI-A was prepared using a procedure
from the literature (24). All other chemicals were purchased
from Sigma unless otherwise stated.
Incubation and electrophoresis. HSA in human plasma was
depleted using a montage albumin deplete kit. Human plasma
(20 μl) was diluted using the equilibration buffer (180 μl)
supplied with the kit and the albumin was depleted according
to the kit procedure. The total protein concentration was
measured using a quick start Bradford protein assay (Bio-Rad,
Reinach, Switzerland). The depleted plasma was separated
into 4 eppendorf vials (150 μl per vial), one vial was used as
control, the others were supplemented with cisplatin (90 μM),
NAMI-A (90 μM), or cisplatin (90 μM) and NAMI-A (90 μM).
Albumin-depleted human plasma was incubated with the
drugs for 24 h at 37˚C in a thermomixer (eppendorf). After
incubation, the samples were stored at -20˚C prior to separation
by electrophoresis. The samples were mixed with sample buffer
(1:4 ratio), either denaturizing sample buffer containing SDS
and DTT for SDS-PAGE, or with non-denaturing sample
buffer for native PAGE. Each sample (20 μl, approximately
1.8 μg/μl total proteins) was applied to a Bio-Rad Tris-HCl
4-20% gel, and separated either with separating buffer
containing SDS for denaturing SDS-PAGE, or buffer without
SDS for native PAGE. Prior to LA-ICP-MS, the gels were
dried overnight between two cellophane sheets. The sample
of human plasma incubated overnight with cisplatin was also
subjected to two-dimensional electrophoresis. The sample was
mixed with rehydration buffer (9 M urea, 2% CHAPS, 0.8%
Pharmalytes 3-10, 15 mM DTT) and applied to an immobilized
pH gradient strip (IPG, Amersham). The sample was allowed
to rehydrate to the IPG strip overnight and then isoelectric
focusing (IEF) was performed using the following program:
14 h at 30 V for rehydration, 1 h at 200 V, 1 h at 500 V, 1 h at
1000 V, 4 h at 8000 V (34,120 Vh total). At the end of IEF, the
strip was equilibrated with SDS in two 15-min equilibration
stages (25) and the proteins were resolved on vertical 8% SDS-
PAGE for second dimension. Proteins resolved on SDS-PAGE
were stained with Coomassie brilliant blue R (Sigma).
For the quantification of platinum and ruthenium bound
to certain proteins, 76 μm of HSA and BSA and 64 μm
transferrin were incubated with a 10-fold concentration of
cisplatin or NAMI-A, or with both cisplatin and NAMI-A.
After incubation overnight, 5 μg of proteins from each sample
were separated with 4-20% SDS-PAGE and stained with
Coomassie blue. The gel was dehydrated with 100% acetonitrile
and dried in air, the dried gel was soaked evenly with rhodium
solution at 10 ppm/g gel, used as an internal standard. A
linear curve was prepared, with 1, 10 and 50 ppm/g gel of
platinum and ruthenium (cisplatin and NAMI-A) soaked in
gel pieces simultaneously with rhodium at 10 ppm/g gel, then
the gel pieces were dried between two cellophane sheets
were used for the preparation of a linear standard curve.
Laser ablation inductively coupled plasma mass spectrometry
(LA-ICP-MS). A PE SCIEX Elan 6100 DRC ICP-MS coupled
with Geolas laser system equipped with lambda physic laser
technology of a 193-nm UV laser was used. The instrument
was operated at 10 Hz/sec, flounce of 19 J/CM2, and pits
diameter size of 120 microns. Helium was used as the carrier
gas with a flow rate of 1.1 l/min, and nebulizer gas at a
0.99 l/min flow rate.
Tryptic digestion of protein PAGE bands. Protein bands
excised from the gel were rehydrated with buffer and destained
with acetonitrile (50 mM ammonium bicarbonate, 1:1). The
destained bands were dehydrated and reswilled with DTT
(10 mM) for reduction (30 min, 56˚C) and alkylated with
iodoacetamide (100 mM) in the dark at room temperature
(30 min). Following further washes with bicarbonate buffer,
the proteins were digested overnight at 37˚C with Promega
trypsin (12.5 ng/μl in 25 mM bicarbonate buffer). Peptides
were extracted with 5% formic acid, followed by acetonitrile,
dried and resuspended in 0.1% formic acid (10 μl) prior to
analysis by ESI-MS.
Mass spectrometry. 1D HPLC-MS/MS was conducted on an
LCQ DECA XP Surveyor LC-MS system (ThermoFinnigan,
San Jose, CA). Chromatographic separation was performed
on a C18 column (5 μm, 100 μm i.d, 100 mm) with a flow
rate of 200 nl/min. The mobile phase consisted of water and
MeCN, and both contained 0.05% (v/v) formic acid. The
HPLC column eluent was eluted directly into the electrospray
ionization source of the LCQ-Deca ion trap mass spectrometer.
Automated peak recognition, dynamic exclusion, and daughter
ion scanning of the top three most intense ions were performed
using Xcalibur software as described previously (26,27).
Spectra were scanned over a range of 500-1800 mass units.
The excitation energy for the precursor ions selected for
collision-induced dissociation was set at 35% (using the
operational parameter ‘% relative collision energy') with a
1-sec activation time. Spectra were interpreted by searches of
product ion mass against the Swissprot database using the
Sequest algorithm.
In vivo experiments. The MCa mammary carcinoma line of
CBA mouse was originally obtained from the Rudjer Boskovic
Institute, Zagreb, Croatia (28). The tumour lines were locally
maintained by serial biweekly passages of 106 viable tumour
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cells, obtained from donors similarly inoculated two weeks
earlier, and injected i.m. (intra-muscularly) into the calves of
the left hind legs of CBA adult mice. Tumour propagation for
experimental purposes was similarly made using CBA mice
obtained from a locally established breeding colony, grown
according to the standard procedure for inbred strains. Briefly,
2.5 g of freshly removed tumour was minced with scissors,
finely dispersed in Dulbecco's phosphate buffer saline, Ca2+
and Mg2+-free (PBS), and filtered through a double layer of
sterile gauze. After centrifugation at 250 x g for 10 min, pellets
were re-suspended in an equal volume of PBS and cell viability
was checked by the trypan-blue exclusion test: only cell
suspensions with at least 55-60% viable cells were used.
In vivo treatments. For in vivo studies, both compounds were
dissolved in isotonic non-pyrogenic physiological saline and
given to mice by i.p. (intraperitoneal) administration. NAMI-A
was used at 35 mg/kg/day on days 7-12 (experiment 1) or on
days 12-17 (experiment 2) after tumour implant. Cisplatin
was given at 8 mg/kg on day 16 (experiment 1) or on day 8
(experiment 2). Compounds were dissolved in an appropriate
volume of physiological saline calculated in order to administer
0.1 ml/10 g of body weight.
Primary tumour growth and lung metastasis evaluation.
Primary tumour growth was determined by calliper measure-
ments, by determining two orthogonal axes and calculating
the tumour volume using the following formula: (π/6)xa2xb,
(a<b) and assuming tumour density equal to one. The
evaluation of the number and weight of lung metastases,
spontaneously formed from the i.m. tumour implants, was
performed at day 21 from tumour implantation, after sacrificing
the animals by cervical dislocation. The number of lung
colonies were counted by carefully examining the surface of
the lungs, dissected into the five lobes, washed with PBS and
examined under a low power microscope equipped with a
calibrated grid. The weight of each metastatic nodule was
calculated by applying the same formula used for primary
tumours; the sum of these individual weights gives the total
weight of the metastatic tumour per animal.
Animal studies. Animal studies were carried out according to
the guidelines in force in Italy (DDL 116 of 21/2/1992) and
in compliance with the Policy on Human Care and Use of
Laboratory Animals, National Institutes of Health, Department
of Health and Human Services, Rockledge Drive, Bethesda,
MD, USA.
Statistical analysis. Data were submitted to computer-assisted
statistical analysis using ANOVA analysis of variance and
Tukey-Kramer post-test.
Results
Pt and Ru protein interaction. Platinum and ruthenium profiles
were similar in SDS- and native PAGE, although there was a
more intense signal for ruthenium binding to transferrin
(Fig. 1A and C). However, there were notable differences in
the profiles and intensities between the SDS- and native PAGE
gels (Fig. 1). In the native gel, dimers of albumin and transferrin
were observed and corresponding intense signals for platinum
and ruthenium were detected (Fig. 1A, C and E). Taking into
account this observation, it is possible to say, overall, that the
signal for platinum and ruthenium is more intense in the
native gel compared to the SDS-PAGE.
Preferential binding of cisplatin and NAMI-A to plasma
proteins was studied by adding both drugs simultaneously to
plasma proteins (Fig. 1E and F). It is evident that the peak
intensity of the platinum corresponding to HSA is higher than
the intensity of the ruthenium peak in SDS-PAGE (Fig. 1F).
Such a difference is absent from the spectrum of native PAGE
(Fig. 1E). On the contrary, the ruthenium peak intensity is
higher in the area of the serotransferrin and macroglobulin ·2
of native PAGE compared to the intensity of platinum.
Since the bands shown in Fig. 1 are broad and could
potentially contain more than one type of protein, two-
dimensional electrophoresis was performed which confirmed
that the identified proteins, serotransferrin and HSA, are indeed
the major proteins that bind platinum; also demonstrating that
treatment of proteins toward two-dimensional electrophoresis
does not have a significant effect on the binding of the different
drugs (Fig. 2).
In order to quantify the binding level of cisplatin and
NAMI-A to transferrin, HSA and BSA, a linear curve with
r2=0.999 was prepared from 1, 10 and 50 ppm of cisplatin
and NAMI-A (see Materials and methods). Subsequently, the
amount of platinum and ruthenium corresponding to cisplatin
and NAMI-A, was quantified and we found that the platinum
concentration was approximately five times higher than the
ruthenium concentration in the proteins (Table I). Competitive
binding of cisplatin and NAMI-A has been tested by incubating
the different proteins with both cisplatin and NAMI-A, which
shows that the binding levels are similar to the binding level
of the drugs incubated separately with the proteins, probably
indicating that the drugs bind to the proteins at different sites
or in different ways.
Antitumour and antimetastatic activity of the combination
therapy. Treatment of mice bearing MCa mammary carcinoma
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Table I. Concentration of platinum and ruthenium bound to






Cisplatin NAMI-A Cisplatin NAMI-A
Pt ppm/g gel Ru ppm/g gel
–––––––––––––––––––––––––––––––––––––––––––––––––
Transferrin 9.6±0.71 1.4±0.08 7.8±0.66 1.2±0.06
HSA 9.0±0.68 1.6±0.08 10.0±0.58 1.7±0.01
BSA 10.6±0.60 1.4±0.10 7.8±0.36 1.3±0.02
–––––––––––––––––––––––––––––––––––––––––––––––––
Concentration of platinum and ruthenium in ppm/g gel. The drugs
cisplatin and NAMI-A incubated separately as in column 2 and 3
with transferrin, HSA, or BSA, or together as in column 4/5. The
difference between cisplatin incubated separately or with NAMI-A
and the difference between NAMI-A incubated separately or with
cisplatin are not significant.
–––––––––––––––––––––––––––––––––––––––––––––––––
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Figure 1. LA-ICP mass spectra/gel profiles of plasma incubated with cisplatin, SDS-PAGE (A); cisplatin, native-PAGE (B); NAMI-A, SDS-PAGE (C);
NAMI-A, native-PAGE; (D); cisplatin/NAMI-A, SDS PAGE; (E) cisplatin/NAMI-A, native PAGE (F).
Figure 2. 2D SDS-PAGE of human plasma incubated with cisplatin; section showing serotransferrin and human serum albumin and the corresponding
LA-ICP-MS of platinum.
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with cisplatin or NAMI-A, or with a combination of the two
drugs with NAMI-A preceding cisplatin or vice-versa, showed
different degrees of toxicity, in terms of lack of body weight
gain during the experiment (Table II). In general, each treatment
alone shows only a low toxicity as expected by the use of
maximally tolerated doses. When combined, the toxicity
increases and is essentially equal to the sum of the individual
toxicity shown by each single agent. Considering the effects
on the primary tumour, determined by comparing the tumour
progression in the treated groups with that of the untreated
controls, it is possible to say that, as expected, NAMI-A is only
weakly active while cisplatin showed a more pronounced
antitumour effect when treatment was performed on early-
stage tumours rather than on advanced tumours.
The effect on the primary tumour can be more fully
appreciated from Fig. 3, which summarises the time curves
of primary tumour growth. The data plotted in Fig. 3 show
that cisplatin stops tumour growth after administration,
independently of whether it was given on early tumours (B)
or on advanced tumours (A). In addition, these data show
that the administration of NAMI-A prior or after cisplatin-
treatment did not modify the MCa mammary carcinoma
response to cisplatin.
Conversely, the combination treatment showed significant
effects compared to the results obtained with each drug, used
as a single agent, on lung metastasis formation and growth
(Table III). In particular, NAMI-A alone showed remarkable
antimetastatic activity, causing approximately 30% of animals
to be free of macroscopically detectable lung metastasis,
independently of whether it was given to mice with early or
advanced tumours. Cisplatin also showed reasonable anti-
metastatic activity although slightly less pronounced than
that of NAMI-A. However, the antimetastatic effect of
cisplatin differs to that of NAMI-A, as can be appreciated by
considering the ratio between metastasis weight and metastasis
number, showing NAMI-A to be much more effective than
cisplatin in reducing metastasis dimensions (0.07-0.065 mg
for NAMI-A and 0.41-0.35 mg for cisplatin). When treatments
with these two drugs were combined in the same animals, a
significantly higher effect was observed in terms of the
number of animals free of macroscopically detectable lung
metastases, which increased to approximately 60% of the
treated animals. If NAMI-A precedes cisplatin, the result
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Table II. Variation of body weight and of primary tumour
weight following the combination treatments with cisplatin
and NAMI-A.
–––––––––––––––––––––––––––––––––––––––––––––––––





NAMI-A alone -10.0 -19.5
(35 mg/kg/day on days 7-12)
Cisplatin alone -13.1 -25.3
(8 mg/kg on day 16)
NAMI-A (35 mg/kg/day on day 7) -21.9 -28.6
+ cisplatin (8 mg/kg on day 16)
2nd experiment
Cisplatin alone -8.00 -50.0
(8 mg/kg on day 8)
NAMI-A alone -4.90 -34.4
(35 mg/kg/day on days 12-17)
Cisplatin (8 mg/kg on day 8) -15.1 -59.0
+ NAMI-A (35 mg/kg/day
on days 12-17) 
–––––––––––––––––––––––––––––––––––––––––––––––––
48 CBA female mice, implanted i.m. with 1x106 MCa mammary
carcinoma cells on day 0, were randomly divided into 4 groups and
given i.p. 35 mg/kg/day NAMI-A on days 7-12, or 8 mg/kg cisplatin
on day 16, or both drugs (experiment 1). Control mice were given
the vehicle (NaCl 0.9%) on days 7-12 and on day 16. In the 2nd
experiment, the treatment with cisplatin, on day 8, preceded the
treatment with NAMI-A on days 12-17. Data are expressed as percent
of variation between before and after treatment versus untreated
controls.
–––––––––––––––––––––––––––––––––––––––––––––––––
Figure 3. Primary tumour growth. CBA female mice (48), implanted i.m.
with 1x106 MCa mammary carcinoma cells on day 0, were randomly
divided into 4 groups and given i.p. 35 mg/kg/day NAMI-A on days 7-12, or
8 mg/kg cisplatin on day 16, or both drugs (A, experiment 1). Control mice
were given the vehicle (NaCl 0.9%) on days 7-12 and on day 16. In a 2nd
analogous experiment (B), the treatment with cisplatin on day 8 preceded
the treatment with NAMI-A on days 12-17. [Statistics: One-way analysis of
variance (ANOVA) and Tukey-Kramer multiple comparison test: a, cisplatin
p<0.01 vs NAMI-A + cisplatin; b, NAMI-A + cisplatin p<0.05 vs controls
and vs cisplatin; c, NAMI-A + cisplatin p<0.05 vs controls; d, cisplatin and
cisplatin + NAMI-A p<0.001 vs controls and vs NAMI-A; e, cisplatin and
cisplatin + NAMI-A p<0.001 vs controls; f, NAMI-A p<0.05 vs controls
and vs cisplatin + NAMI-A].
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shows a pronounced increase as compared to the single
treatment (60.0% vs 33.3%) and, when cisplatin preceded
NAMI-A, the number of animals free of macroscopically
detectable lung metastasis was equal to the sum of those
observed in the groups treated with each single agent alone
(62.5% vs 63.3%).
Discussion
The need for general screening methods to test metal drug-
protein interactions in the biological system is increasing in
order to cover the wide and diverse range of compounds and
for high throughput analysis and evaluation of newly developed
drugs or existing drugs in novel combinations. Since the
function of metal drugs is highly influenced by plasma
proteins, we decided to examine the plasma protein-drug
interactions for two important drugs, cisplatin and NAMI-A,
and compare the results to pharmacological data in order to see
if a connection could be made between in vitro and in vivo
systems. Such a goal is particularly important since NAMI-A
failed in vitro evaluation and could easily have been omitted
from further evaluation (negative data from the NCI protocols
for the screening of chemical agents on the 60-panel cell
lines). In order to directly compare the interaction of cisplatin
and NAMI-A with plasma proteins, samples of the two
drugs, and a mixture of the two, were incubated with human
plasma proteins (in which the albumin had been depleted) for
24 h at 37˚C. Following incubation, the plasma protein-drug
samples were partially separated using native PAGE and
SDS-PAGE gel electrophoresis in order to delineate differences
between covalent and non-covalent binding of the drugs with
the plasma proteins. The gels were then analysed by laser
ablation inductively coupled plasma mass spectrometry, in
which the gel is scanned with a laser, which ablates the sample,
and the resulting desorption plume is extracted under vacuum,
converted to a plasma, and the elemental composition of the
plasma is determined by mass spectrometry. ICP-MS is a
powerful and highly sensitive technique for elemental analysis,
and has been widely used when interfaced with HPLC for the
analysis of metals in biological samples (30,31). Combined
with laser ablation, ICP-MS has been used to analyse metallo-,
seleno- or phospho-proteins resolved by PAGE (26,27,32,33).
Accordingly, elements such as platinum and ruthenium,
which are not naturally present in living systems are readily
identified and quantified. The spectra obtained from the
LA-ICP-MS experiments, superimposed with their cor-
responding gels, are shown in Fig. 1, from which a global
view of the binding of the drugs to the plasma proteins can be
immediately appreciated, thereby allowing a direct comparison
between the two drugs.
In order to identify the chief proteins that interact with
cisplatin and NAMI-A, the protein bands corresponding to
the most intense platinum and ruthenium peaks were excised
from the gels and the proteins were identified using proteomics
methods (see below). Three major platinum and ruthenium
peaks are present in the profile of plasma separated with
SDS-PAGE, which correspond to three different proteins,
viz. human serum albumin (HSA) precursor, human sero-
transferrin precursor and macroglobulin ·2. These proteins
were characterised using LC-MS-MS with the Sequest
algorithm search of the spectra against the Swissprot database,
and the identity of the proteins was confirmed with 49.3%
amino acid coverage of HSA precursor, 32.7% of human
serotransferrin and 34.7% of macroglobulin ·2. 
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Number Weight (mg) Animals free (%)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
1st experiment
Controls (NaCl 0.9% on days 7-12 and 16) 22.1±5.63 12.2±5.87 0
NAMI-A alone (35 mg/kg/day on days 7-12) 7.83±2.49a 0.580±0.140a 33.3
Cisplatin alone (8 mg/kg on day 16) 9.33±2.88 3.84±1.28 0
NAMI-A (35 mg/kg/day on day 7) 7.75±2.13a 0.500±0.140a 60
+ cisplatin (8 mg/kg on day 16)
2nd experiment
Controls (NaCl 0.9% on days 8 and 12-17) 58.7±11.0 42.2±9.80 11.1
Cisplatin alone (8 mg/kg on day 8) 11.0±2.20b 3.90±1.60b 33.3
NAMI-A alone (35 mg/kg/day on days 12-17) 15.3±4.60b 1.00±0.300b 30.0
Cisplatin (8 mg/kg on day 8)  7.70±5.20b 0.500±0.300b 62.5
+ NAMI-A (35 mg/kg/day on days 12-17)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
CBA female mice (48), implanted i.m. with 1x106 MCa mammary carcinoma cells on day 0, were randomly divided into 4 groups and given
i.p. 35 mg/kg/day NAMI-A, or 8 mg/kg cisplatin on the days indicated, or both drugs. Control mice were given the vehicle (NaCl 0.9%) on
the same days. Lung metastases were determined on day 21. [Statistics: One-way analysis of variance (ANOVA) and Tukey-Kramer
multiple comparison test: ap<0.05 vs controls; bp<0.001 vs controls].
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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Four major platinum and ruthenium peaks are present in
the profile of the plasma separated on native PAGE which
correspond to HSA precursor (observed as monomer and dimer)
and human serotransferrin precursor (observed as monomer
and dimer), and characterised with essentially the same %
amino acid coverage.
Analysing and comparing the differential binding of
cisplatin and NAMI-A drugs to plasma proteins resolved on
PAGE, adopting the methodology that had been employed
previously to analyse platinum binding plasma proteins and
platinum binding E. coli whole cell proteins (23,34), we
obtained spectra remarkably similar for both drugs, although
the level of cisplatin binding is approximately 5-fold higher
than that of NAMI-A. The most intense and prominent signals
come from HSA and transferrin, and the results are consistent
with pharmaceutical and plasma protein studies which show
that albumin and transferrin correspond to the proteins that
bind platinum and ruthenium anti-cancer drugs (14,19,35). The
native binding of both drugs to the plasma proteins is similar.
However, using a reducing agent, such as DTT, and SDS for
the denaturising of proteins, the drug binding is interrupted,
only partially but to a greater extent for the ruthenium
compound. Dual incubation of plasma with cisplatin and
NAMI-A appears to exhibit no competition between the
platinum and ruthenium drugs as it is possible to observe
similar signals either with the drugs incubated alone or in
combination. This implies that the different drugs bind to
different sites on the proteins, at least in the case of transferrin
and albumin.
This study represents the first report comparing the
quantitative binding of cisplatin and NAMI-A, using LA-
ICP-MS. The data reported in this study are consistent with
reports in the literature that the binding level of NAMI-A is
similar either to transferrin or to albumin (35). With the results
here, it is possible to see that cisplatin also binds to transferrin
and albumin in approximately equal quantities. It has been
proposed that albumin is able to tightly bind at least five
ruthenium equivalents when BSA is incubated with NAMI-A
(19). The above assumption could be true for binding quantifi-
cation under native conditions. However, the covalent binding
quantification in this study shows that NAMI-A bind almost
ten times less than cisplatin to either transferrin or albumin.
Combination therapy represents one of the most successful
ways to treat cancer and cisplatin is usually administered
together with other drugs for increased effect. It is likely that
once NAMI-A progresses further through clinical trials it
may prove to be more effective in preventing metastases
when administered with cisplatin, which induces apoptosis.
Since binding to plasma proteins is implicated in the transport
mechanism for both drugs (9,29), it is interesting to see whether
the simultaneous addition of both drugs to plasma results in
significant differences in binding, i.e. cisplatin could block
NAMI-A binding to certain proteins or vice versa, even if in
any potential combination therapy the drugs are administered
at different times. Concerning the relevance of plasma protein
binding of cisplatin and NAMI-A for their activity against
tumour growth, the combined experiments performed in mice
with MCa mammary carcinoma seem to suggest the lack of
any negative influence, independently of whether NAMI-A
is given prior to or after cisplatin, and the overall result is
globally better than that of each treatment taken alone. The
increase of host toxicity, in terms of lack of body weight gain,
is probably due to the intrinsic nature of these compounds,
both being based on a heavy metal and thus being toxic to the
kidneys. Although NAMI-A toxicity on kidneys is reversible
upon a sufficient wash-out, we cannot exclude the possibility
that the irreversible damage caused by cisplatin could be
more severe and long lasting after combined treatment with
NAMI-A. However, the pharmacological data reported here
demonstrate the compatibility of the concomitant treatment
with two metal-based drugs (the platinum drug, cisplatin, and
the ruthenium compound, NAMI-A) for treating malignant
carcinomas. The overall effect observed is in fact the sum of
the combination of the cytotoxic efficacy of cisplatin and of
the metastasis inhibition of NAMI-A in both experiments
performed, independently of the sequence of administration
of the two drugs. Thus, they would appear to maintain their
individual binding sites on plasma proteins without any
interference from each other (as shown by the LA-ICP-MS
study), and they also maintain their individual targets and
mechanisms of action on cancer cells. These results highlight
the potential usefulness for a compound such as NAMI-A for
the treatment of disseminated tumours in combination with
conventional cytotoxic drugs.
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